Emerging Therapeutic Strategies for COVID-19 Patients
Argus Pharmaceuticals, Changsha, China, Shudong Zhu, Xialing Guo, Argus Pharmaceuticals, Changsha, China, Kyla Geary, Dianzheng Zhang
Abstract
Over 100,000 cases of COVID-19 patients infected with the novel coronavirus SARS-COV-2 have been reported worldwide in approximately 2 months, resulting in over 3000 deaths. Potential therapeutic strategies, including remdesivir, chloroquine phosphate, abidol, lopinavir/ritonavir, plasma, antibody, vaccine and stem cells are discussed in this review. With the number of patients increasing daily, there is an urgent need for effective therapeutic intervention.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Lopinavir/ritonavirLopinavirMedicineChloroquineConvalescent plasmaRitonavirSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakHydroxychloroquineVirologyIntensive care medicineTherapeutic approachImmunologyVirusInternal medicineViral loadAntiretroviral therapyOutbreakDiseaseMalariaInfectious disease (medical specialty)COVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Vitamin C and Antioxidants Research